Edgewise Therapeutics Shares Tumble on Underwritten Public Offering Pricing

Dow Jones

04-02

By Denny Jacob

Edgewise Therapeutics shares tumbled 29% in premarket trading on Wednesday after pricing its underwritten public offering of 9.9 million shares of its common stock.

Shares were trading around $17.98. The stock is up 8.8% over the last year.

The muscle disease biopharmaceutical company's offering price for its public offer is $20.13 a share, which it expects will bring in gross proceeds of $200 million before expenses.

The offer is expected to occur on Thursday. Edgewise intends to use the net proceeds from the offering to support the potential U.S. launch of sevasemten in patients with Becker muscular dystrophy, if approved, among other efforts.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

April 02, 2025 08:07 ET (12:07 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2524671694"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2524671694\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2524671694?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-02 20:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524671694","market":"sg","top_or_hot":-1,"title":"Edgewise Therapeutics Shares Tumble on Underwritten Public Offering Pricing","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Edgewise <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares tumbled 29% in premarket trading on Wednesday after pricing its underwritten public offering of 9.9 million shares of its common stock. \n</p>\n<p>\n  Shares were trading around $17.98. The stock is up 8.8% over the last year. \n</p>\n<p>\n  The muscle disease biopharmaceutical company's offering price for its public offer is $20.13 a share, which it expects will bring in gross proceeds of $200 million before expenses. \n</p>\n<p>\n  The offer is expected to occur on Thursday. Edgewise intends to use the net proceeds from the offering to support the potential U.S. launch of sevasemten in patients with Becker muscular dystrophy, if approved, among other efforts. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 02, 2025 08:07 ET (12:07 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Edgewise Therapeutics Shares Tumble on Underwritten Public Offering Pricing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEdgewise Therapeutics Shares Tumble on Underwritten Public Offering Pricing\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-04-02 20:07</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Edgewise <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares tumbled 29% in premarket trading on Wednesday after pricing its underwritten public offering of 9.9 million shares of its common stock. \n</p>\n<p>\n  Shares were trading around $17.98. The stock is up 8.8% over the last year. \n</p>\n<p>\n  The muscle disease biopharmaceutical company's offering price for its public offer is $20.13 a share, which it expects will bring in gross proceeds of $200 million before expenses. \n</p>\n<p>\n  The offer is expected to occur on Thursday. Edgewise intends to use the net proceeds from the offering to support the potential U.S. launch of sevasemten in patients with Becker muscular dystrophy, if approved, among other efforts. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 02, 2025 08:07 ET (12:07 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2524671694","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524671694","pubTimestamp":1743595620,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Edgewise Therapeutics shares tumbled 29% in premarket trading on Wednesday after pricing its underwritten public offering of 9.9 million shares of its common stock.Shares were trading around $17.98. The stock is up 8.8% over the last year.The muscle disease biopharmaceutical company's offering price for its public offer is $20.13 a share, which it expects will bring in gross proceeds of $200 million before expenses.The offer is expected to occur on Thursday. Edgewise intends to use the net proceeds from the offering to support the potential U.S. launch of sevasemten in patients with Becker muscular dystrophy, if approved, among other efforts.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4539":"次新股","BK4007":"制药","LENZ":"Therapeutics","EWTX":"Edgewise Therapeutics, Inc."},"translate_title":"Edgewise Therapeutics股价因承销公开发行定价而暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EWTX":1,"LENZ":1},"content_text":"By Denny Jacob \n\n\n \n\n\n  Edgewise Therapeutics shares tumbled 29% in premarket trading on Wednesday after pricing its underwritten public offering of 9.9 million shares of its common stock. \n\n\n  Shares were trading around $17.98. The stock is up 8.8% over the last year. \n\n\n  The muscle disease biopharmaceutical company's offering price for its public offer is $20.13 a share, which it expects will bring in gross proceeds of $200 million before expenses. \n\n\n  The offer is expected to occur on Thursday. Edgewise intends to use the net proceeds from the offering to support the potential U.S. launch of sevasemten in patients with Becker muscular dystrophy, if approved, among other efforts. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 02, 2025 08:07 ET (12:07 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}